Dermira (Dermira) Days Payable : 538.34 (As of Sep. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Dermira Days Payable?

Dermira's average Accounts Payable for the three months ended in Sep. 2019 was $11.40 Mil. Dermira's Cost of Goods Sold for the three months ended in Sep. 2019 was $1.93 Mil. Hence, Dermira's Days Payable for the three months ended in Sep. 2019 was 538.34.

The historical rank and industry rank for Dermira's Days Payable or its related term are showing as below:

DERM's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 146.16
* Ranked among companies with meaningful Days Payable only.

Dermira's Days Payable declined from Sep. 2018 (4,968.70) to Sep. 2019 (538.34). It may suggest that Dermira accelerated paying its suppliers.

Dermira Days Payable Historical Data

The historical data trend for Dermira's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermira Days Payable Chart

Dermira Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Days Payable

Get a 7-Day Free Trial

4,817.32

Dermira Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Days Payable	Get a 7-Day Free Trial															4,968.70	1,429.15	1,085.39	602.52	538.34

Competitive Comparison of Dermira's Days Payable

For the Biotechnology subindustry, Dermira's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermira's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's Days Payable distribution charts can be found below:

* The bar in red indicates where Dermira's Days Payable falls into.

Dermira Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Dermira's Days Payable for the fiscal year that ended in Dec. 2018 is calculated as

	Days Payable (A: Dec. 2018 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2017 )	+	Accounts Payable (A: Dec. 2018 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2018 )	*	Days in Period
=	( (15.094	+	15.948)	/	2 )	/	1.176	*	365
=	15.521					/	1.176	*	365
=	4,817.32

Dermira's Days Payable for the quarter that ended in Sep. 2019 is calculated as:

	Days Payable (Q: Sep. 2019 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2019 )	+	Accounts Payable (Q: Sep. 2019 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2019 )	*	Days in Period
=	( (11.549	+	11.247)	/	2 )	/	1.932	*	365 / 4
=	11.398					/	1.932	*	365 / 4
=	538.34

Dermira Days Payable Related Terms

Thank you for viewing the detailed overview of Dermira's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermira (Dermira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025

Website

http://www.dermira.com

Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.

Executives

Halley E Gilbert	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo	director
Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans	director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime	officer: CFO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams	officer: Chief Commercial Officer	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer	director, officer: Chief Medical Officer	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc	director	285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp	director	2765 SAND HILL RD, MENLO PARK CA 94025